Gossamer Bio, Inc.

• FundamentalsWhat is this?HideNot scored — outside AIR's $300M–$20B fundamentals band

  How the business is doing on its own reported US-GAAP numbers — growth, margins, cash generation, balance-sheet strength, capital efficiency and dilution — compared with sector peers.

  Source: SEC XBRL financial statements.

• ValueWhat is this?HideToo few of the required measures on file

  How the shares are priced against sector peers, against the company's own recent history, and against a simple cash-flow estimate, using the filing numbers and the current price. AIR shows this as a band, never as a target price.

  Source: SEC XBRL financial statements and end-of-day prices.

• News flowWhat is this?HideBalanced

  What the company has documented recently: material 8-K events (contracts, deals, results, leadership changes) and FDA approvals, weighted by recency and type. A language model's reading of each 8-K helps classify whether it is positive or negative. Filings, not press or social media.

  Source: SEC EDGAR 8-K filings and FDA approvals.

• MomentumWhat is this?HideWeak

  The longer-term market read: the trend in end-of-day prices, strength against the market and the sector, and trading volume over roughly the past three to twelve months. It is shown, never used to rank the Shortlist.

  Source: End-of-day prices.

• SafetyWhat is this?HideWatch

  The risk side: leverage, liquidity, cash runway, dilution, revenue and margin swings, company size and pre-commercial status, negative 8-K events (including legal and regulatory ones), and share-price drawdown and volatility. Higher means fewer of those risk markers.

  Source: SEC XBRL financial statements, SEC EDGAR 8-K filings and end-of-day prices.

Overall confidence 39/100 — few inputs available yet